HRP20200921T1 - Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 - Google Patents
Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 Download PDFInfo
- Publication number
- HRP20200921T1 HRP20200921T1 HRP20200921TT HRP20200921T HRP20200921T1 HR P20200921 T1 HRP20200921 T1 HR P20200921T1 HR P20200921T T HRP20200921T T HR P20200921TT HR P20200921 T HRP20200921 T HR P20200921T HR P20200921 T1 HRP20200921 T1 HR P20200921T1
- Authority
- HR
- Croatia
- Prior art keywords
- agent
- antibody
- seq
- cancer
- use according
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000025171 antigen binding proteins Human genes 0.000 claims 5
- 108091000831 antigen binding proteins Proteins 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- -1 auristatinPE Chemical compound 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
1. Prvo sredstvo i drugo sredstvo za upotrebu u liječenju ili prevenciji hiperproliferativne bolesti povezane sa HER-3,
naznačeno time što je navedena hiperproliferativna bolest rak koji izražava ili prekomjerno izražava HER-3,
navedeno prvo sredstvo je antigen-vezujući protein koji se veže za HER-3, i sadrži: aminokiselinsku sekvencu teškog lanca koja sadrži CDRH1 kao što je prikazano u sekvenci SEQ ID NO: 256; CDRH2 kao što je prikazano u sekvenci SEQ ID NO: 282; i CDRH3 kao što je prikazano u sekvenci SEQ ID NO: 315; i aminokiselinsku sekvencu lakog lanca koja sadrži CDRL1 kao što je prikazano u sekvenci SEQ ID NO: 340; CDRL2 kao što je prikazano u sekvenci SEQ ID NO: 344; i CDRL3 kao što je prikazano u sekvenci SEQ ID NO: 387 i pri čemu je drugo sredstvo pertuzumab.
2. Prvo sredstvo i drugo sredstvo za upotrebu prema patentnom zahtjevu 1, naznačeno time što navedeno prvo sredstvo je antigen-vezujući protein koji se veže za HER-3, i sadrži aminokiselinsku sekvencu teškog lanca kao što je prikazano u sekvenci SEQ ID NO: 70 ili/i aminokiselinsku sekvencu lakog lanca kao što je prikazano u sekvenci SEQ ID NO: 72.
3. Prvo sredstvo i drugo sredstvo za upotrebu prema patentnom zahtjevu 1 ili 2, naznačeno time što navedeno prvo sredstvo je antigen-vezujući protein koji se veže za HER-3, i sadrži aminokiselinsku sekvencu teškog lanca SEQ ID NO: 70 i aminokiselinsku sekvencu lakog lanca SEQ ID NO: 72.
4. Prvo sredstvo i drugo sredstvo za upotrebu prema patentnom zahtjevu 3, naznačeno time što je navedeni antigen-vezujući protein usmjeren protiv ekstracelularne domene HER-3, ili smanjuje prijenos signala posredovan sa HER-3, ili smanjuje fosforilaciju HER-3, ili smanjuje staničnu proliferaciju, ili smanjuje staničnu migraciju ili/i povećava silaznu regulaciju HER-3.
5. Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što navedeni antigen-vezujući protein koji se veže za HER-3 je antitijelo, naročito monoklonsko antitijelo, poliklonsko antitijelo, rekombinantno antitijelo, humanizirano antitijelo, ljudsko antitijelo, himerno antitijelo, multispecifično antitijelo, ili njihov fragment antitijela, naročito Fab fragment, Fab' fragment, F(ab')2 fragment, Fv fragment, diatijelo, ili molekula jednolančanog antitijela, naročito antitijelo tipa IgG1, IgG2, IgG3 ili IgG4.
6. Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od patentnih zahtjeva 1-5, naznačeno time što je navedeno prvo sredstvo vezano za efektorsku grupu, naročito za radioizotop ili radionuklid, toksin, ili terapijsku ili kemoterapijsku grupu, gdje je terapijska ili kemoterapijska grupa poželjno kaliheamicin, auristatinPE, geldanamicin, majtanzin i njihovi derivati.
7. Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od patentnih zahtjeva 1-6, naznačeno time što navedeno liječenje ili prevencija sadrži primjenu dodatnog terapijskog sredstva i/ili zračne terapije, gdje je dodatno terapijsko sredstvo poželjno antineoplastično sredstvo ili antitumorsko antitijelo ili kemoterapijsko sredstvo, gdje je kemoterapijsko sredstvo poželjno izabrano iz grupe koja se sastoji od kapecitabina, antraciklina, doksorubicina, ciklofosfamida, paklitaksela, docetaksela, cisplatina, gemcitabina i karboplatina.
8. Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od patentnih zahtjeva 1-7, naznačeno time što su navedeno prvo sredstvo i navedeno drugo sredstvo za primjenu intravenskom, subkutanom, intramuskularnom ili oralnom primjenom.
9. Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od patentnih zahtjeva 1-8, naznačeno time što je navedena hiperproliferativna bolest izabrana iz grupe koja se sastoji od raka dojke, raka jajnika, raka prostate, raka debelog crijeva, raka bubrega, raka pluća, raka gušterače, epidermoidnog raka, fibrosarkoma, melanoma, nazofaringealnog raka, i raka rožnatih stanica.
10. Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od patentnih zahtjeva 1-9, naznačeno time što navedeno liječenje ili prevencija sadrži primjenu navedenog prvog sredstva ili drugog sredstva u dozi od oko 1 do oko 20 mg/kg tjelesne težine, najmanje jednom na svakih 6 tjedana.
11. Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od patentnih zahtjeva 1-10, naznačeno time što navedeno liječenje ili prevencija dalje sadrži, nakon primjene na subjekta, praćenje terapijskog ishoda.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26114909P | 2009-11-13 | 2009-11-13 | |
EP17197711.9A EP3351558B1 (en) | 2009-11-13 | 2010-11-12 | Material and methods for treating or preventing her-3 associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200921T1 true HRP20200921T1 (hr) | 2020-09-18 |
Family
ID=43618172
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180104TT HRP20180104T1 (hr) | 2009-11-13 | 2018-01-19 | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 |
HRP20200921TT HRP20200921T1 (hr) | 2009-11-13 | 2020-06-08 | Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180104TT HRP20180104T1 (hr) | 2009-11-13 | 2018-01-19 | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 |
Country Status (25)
Country | Link |
---|---|
US (4) | US9101760B2 (hr) |
EP (5) | EP3670539A1 (hr) |
JP (5) | JP5931736B2 (hr) |
KR (1) | KR101806323B1 (hr) |
CN (2) | CN105999263B (hr) |
AR (1) | AR080564A1 (hr) |
AU (1) | AU2010319483B2 (hr) |
BR (1) | BR112012012160B1 (hr) |
CA (1) | CA2780935C (hr) |
CY (2) | CY1119751T1 (hr) |
DK (2) | DK3351558T3 (hr) |
ES (3) | ES2655737T3 (hr) |
HK (1) | HK1207651A1 (hr) |
HR (2) | HRP20180104T1 (hr) |
HU (2) | HUE049880T2 (hr) |
LT (2) | LT3351558T (hr) |
MX (3) | MX349513B (hr) |
NO (1) | NO2719708T3 (hr) |
PL (2) | PL3351558T3 (hr) |
PT (2) | PT2719708T (hr) |
RS (2) | RS56741B1 (hr) |
SI (2) | SI2719708T1 (hr) |
TW (1) | TWI630916B (hr) |
UY (1) | UY33034A (hr) |
WO (1) | WO2011060206A2 (hr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
RU2451524C2 (ru) | 2005-11-04 | 2012-05-27 | Вайет | Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272 |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2310011B1 (en) | 2008-06-17 | 2013-07-24 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
KR101434009B1 (ko) | 2008-08-04 | 2014-08-25 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
JP2013505899A (ja) | 2009-09-28 | 2013-02-21 | チールー ファーマシューティカル カンパニー、リミテッド | チロシンキナーゼ阻害剤として有用な4−(置換アニリノ)キナゾリン誘導体 |
EP2494046B1 (en) | 2009-10-30 | 2018-09-12 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
AU2015201262B2 (en) * | 2009-11-13 | 2017-04-27 | Amgen Inc. | Material and methods for treating or preventing her-3 associated diseases |
KR20120098911A (ko) | 2009-12-22 | 2012-09-05 | 로슈 글리카트 아게 | 항-her3 항체 및 이의 용도 |
US9512199B2 (en) | 2010-07-30 | 2016-12-06 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
CN105037552B (zh) | 2010-08-20 | 2019-03-29 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
ES2692379T3 (es) | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
SG11201400150TA (en) | 2011-09-30 | 2014-03-28 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
CN104053670A (zh) | 2011-10-31 | 2014-09-17 | 百时美施贵宝公司 | 具有降低的免疫原性的纤连蛋白结合域 |
MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
AU2012349735B2 (en) * | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
WO2013084151A2 (en) * | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
US20150037336A1 (en) * | 2012-02-22 | 2015-02-05 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
CN104136464A (zh) | 2012-02-23 | 2014-11-05 | U3制药有限公司 | 用于调节放射敏感性的her3抑制剂 |
US9527913B2 (en) * | 2012-05-02 | 2016-12-27 | Symphogen A/S | Humanized pan-HER antibody compositions |
JP2015526435A (ja) * | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | 抗体成分と血液脳関門を通過するポリペプチドと細胞毒とを含むコンジュゲート |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
US20160213760A1 (en) * | 2012-11-12 | 2016-07-28 | Angiochem Inc. | Aprotinin-derived polypeptide-antibody conjugates |
AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
DK3129063T3 (da) * | 2014-04-10 | 2021-04-06 | Daiichi Sankyo Co Ltd | Anti-her3-antistof-lægemiddelkonjugat |
US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
EP3191523B1 (en) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
CN104861068B (zh) * | 2015-01-23 | 2020-11-17 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗her3抗体及其治疗相关疾病的用途 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
JP6823055B2 (ja) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | 軟髄膜癌腫症の治療方法 |
HUE061408T2 (hu) | 2015-06-29 | 2023-06-28 | Daiichi Sankyo Co Ltd | Eljárás antitest-gyógyszer konjugátum szelektív elõállítására |
WO2017102789A1 (en) * | 2015-12-17 | 2017-06-22 | F. Hoffmann-La Roche Ag | Combination therapy of anti-her3 antibodies and anti-her2 antibodies |
JP7203426B2 (ja) | 2016-09-15 | 2023-01-13 | ウニヴェルズィテート シュトゥットガルト | Her3に対する抗原結合タンパク質 |
SG10201912575RA (en) | 2016-12-12 | 2020-02-27 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
TWI780104B (zh) | 2017-01-17 | 2022-10-11 | 日商第一三共股份有限公司 | 抗gpr20抗體及抗gpr20抗體-藥物結合物、以及其製造方法及用途 |
JP7181181B2 (ja) * | 2017-02-28 | 2022-11-30 | 第一三共株式会社 | 抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法 |
EP3615067A1 (en) | 2017-04-28 | 2020-03-04 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
TWI794230B (zh) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | 抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法 |
SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
CN111051330A (zh) | 2017-08-31 | 2020-04-21 | 第一三共株式会社 | 抗体-药物缀合物的改进制备方法 |
US20210221910A1 (en) | 2018-05-18 | 2021-07-22 | Glycotope Gmbh | Anti-muc1 antibody |
WO2019241893A2 (en) * | 2018-06-22 | 2019-12-26 | Crd Pharmaceuticals Inc | Anti-her3 antibody and uses thereof |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
EP4096781A1 (en) | 2020-01-28 | 2022-12-07 | RefleXion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
WO2023165475A1 (zh) * | 2022-03-03 | 2023-09-07 | 四川科伦博泰生物医药股份有限公司 | Her3结合蛋白及其用途 |
TW202400245A (zh) * | 2022-04-29 | 2024-01-01 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 抗體藥物偶聯物及其製備方法和用途 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467383A (en) | 1974-06-12 | 1977-03-16 | Farmaceutici Italia | Daunomycin analogues |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
US4471052A (en) | 1982-01-18 | 1984-09-11 | Adria Laboratories, Inc. | Biosynthesis of simplified anthracyclines |
JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US4939168A (en) | 1989-08-11 | 1990-07-03 | Harbor Branch Oceanographics Institution, Inc. | Discodermolide compounds, compositions containing same and methods of preparation and use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
NZ253943A (en) | 1992-06-18 | 1997-01-29 | Genpharm Int | Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
FR2718135B1 (fr) | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Procédé de préparation d'hydroxy-7 taxanes. |
FR2721928A1 (fr) | 1994-07-04 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
TW321649B (hr) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
US5837815A (en) | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
AU718138B2 (en) | 1995-08-29 | 2000-04-06 | Kyowa Hakko Kirin Co., Ltd. | Chimeric animal and method for constructing the same |
US5681847A (en) | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
CA2246429C (en) | 1996-03-27 | 2007-07-24 | Genentech, Inc. | Erbb3 antibodies |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
US6114595A (en) | 1996-04-11 | 2000-09-05 | The Procter & Gamble Company | Stretchable, extensible composite topsheet for absorbent articles |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
AU5596998A (en) | 1996-12-11 | 1998-07-03 | New York University Medical Center | Pyk2 related products and methods |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
KR20070087132A (ko) | 1998-11-20 | 2007-08-27 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법및 물질 |
AU2209899A (en) | 1998-12-30 | 2000-07-24 | Sugen, Inc. | Pyk2 (raftk) and inflammation |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
FR2817258B1 (fr) | 2000-11-27 | 2003-01-10 | Atofina | Procede de sulfochloration photochimique d'alcanes gazeux |
IL152420A0 (en) | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
DK2319301T3 (en) | 2001-11-30 | 2017-12-04 | Amgen Fremont Inc | Transgenic animals with human Ig lambda light chain genes |
EP1554576B9 (en) | 2001-12-03 | 2008-08-20 | Amgen Fremont Inc. | Identification of high affinity molecules by limited dilution screening |
EP2400021B1 (en) | 2002-03-26 | 2016-11-30 | Zensun (Shanghai) Science & Technology, Co., Ltd. | ErbB3 based methods and compositions for treating neoplasms |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
WO2004011900A2 (en) | 2002-07-25 | 2004-02-05 | Aclara Biosciences, Inc. | Detecting receptor oligomerization |
MXPA05005921A (es) | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
BRPI0408928A (pt) | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
SI1859041T2 (sl) | 2005-02-18 | 2015-04-30 | Angiochem Inc. | Polipeptidi aprotinina za prenos spojine prek krvno-moĹľganske pregrade |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
BRPI0520530A2 (pt) * | 2005-10-05 | 2009-09-29 | Astrazeneca Uk Ltd | método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
ES2431940T3 (es) | 2007-02-16 | 2013-11-28 | Merrimack Pharmaceuticals, Inc. | Anticuerpos contra la ERBB3 y usos de los mismos |
GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
BR112012003809A2 (pt) * | 2009-08-21 | 2019-09-24 | Merrimack Pharmaceuticals Inc | anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. |
-
2010
- 2010-11-12 PT PT131890923T patent/PT2719708T/pt unknown
- 2010-11-12 EP EP20151640.8A patent/EP3670539A1/en active Pending
- 2010-11-12 TW TW099139038A patent/TWI630916B/zh active
- 2010-11-12 KR KR1020127015255A patent/KR101806323B1/ko active IP Right Grant
- 2010-11-12 US US12/944,764 patent/US9101760B2/en active Active
- 2010-11-12 PL PL17197711T patent/PL3351558T3/pl unknown
- 2010-11-12 JP JP2012538994A patent/JP5931736B2/ja active Active
- 2010-11-12 CA CA2780935A patent/CA2780935C/en active Active
- 2010-11-12 MX MX2012005589A patent/MX349513B/es active IP Right Grant
- 2010-11-12 LT LTEP17197711.9T patent/LT3351558T/lt unknown
- 2010-11-12 ES ES13189092.3T patent/ES2655737T3/es active Active
- 2010-11-12 NO NO13189092A patent/NO2719708T3/no unknown
- 2010-11-12 EP EP13189092.3A patent/EP2719708B1/en active Active
- 2010-11-12 SI SI201031627T patent/SI2719708T1/en unknown
- 2010-11-12 MX MX2016008205A patent/MX358013B/es unknown
- 2010-11-12 BR BR112012012160-0A patent/BR112012012160B1/pt active IP Right Grant
- 2010-11-12 RS RS20180048A patent/RS56741B1/sr unknown
- 2010-11-12 HU HUE17197711A patent/HUE049880T2/hu unknown
- 2010-11-12 WO PCT/US2010/056430 patent/WO2011060206A2/en active Application Filing
- 2010-11-12 DK DK17197711.9T patent/DK3351558T3/da active
- 2010-11-12 MX MX2016002120A patent/MX357972B/es unknown
- 2010-11-12 AU AU2010319483A patent/AU2010319483B2/en active Active
- 2010-11-12 PL PL13189092T patent/PL2719708T3/pl unknown
- 2010-11-12 LT LTEP13189092.3T patent/LT2719708T/lt unknown
- 2010-11-12 HU HUE13189092A patent/HUE035605T2/en unknown
- 2010-11-12 RS RS20200651A patent/RS60390B1/sr unknown
- 2010-11-12 PT PT171977119T patent/PT3351558T/pt unknown
- 2010-11-12 EP EP10785251A patent/EP2499162A2/en not_active Withdrawn
- 2010-11-12 DK DK13189092.3T patent/DK2719708T3/da active
- 2010-11-12 SI SI201032011T patent/SI3351558T1/sl unknown
- 2010-11-12 EP EP15154165.3A patent/EP2896632B1/en active Active
- 2010-11-12 EP EP17197711.9A patent/EP3351558B1/en active Active
- 2010-11-12 ES ES17197711T patent/ES2781299T3/es active Active
- 2010-11-12 ES ES15154165.3T patent/ES2647466T3/es active Active
- 2010-11-12 CN CN201610373755.5A patent/CN105999263B/zh active Active
- 2010-11-12 CN CN201080052236.XA patent/CN102812045B/zh active Active
- 2010-11-15 UY UY33034A patent/UY33034A/es not_active Application Discontinuation
- 2010-11-15 AR ARP100104211 patent/AR080564A1/es unknown
-
2013
- 2013-04-25 US US13/870,796 patent/US9803025B2/en active Active
-
2015
- 2015-08-20 HK HK15108089.8A patent/HK1207651A1/xx unknown
-
2016
- 2016-01-05 JP JP2016000552A patent/JP6235620B2/ja active Active
- 2016-01-18 US US15/000,005 patent/US9988462B2/en active Active
-
2017
- 2017-10-26 JP JP2017206911A patent/JP2018076300A/ja active Pending
- 2017-10-27 US US15/796,361 patent/US20180134805A1/en active Pending
- 2017-12-13 CY CY20171101305T patent/CY1119751T1/el unknown
-
2018
- 2018-01-19 HR HRP20180104TT patent/HRP20180104T1/hr unknown
-
2019
- 2019-09-20 JP JP2019172295A patent/JP7317650B2/ja active Active
-
2020
- 2020-06-05 CY CY20201100505T patent/CY1123030T1/el unknown
- 2020-06-08 HR HRP20200921TT patent/HRP20200921T1/hr unknown
-
2021
- 2021-09-17 JP JP2021152652A patent/JP2022000445A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200921T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 | |
JP2013510868A5 (hr) | ||
JP2020011980A5 (hr) | ||
HRP20150443T1 (hr) | Djelotvorne tvari koje se vežu za notch i njihovi antagonisti te postupci njihove uporabe | |
RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
JP2021531764A5 (hr) | ||
JP2017514795A5 (hr) | ||
WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
JP2008531576A5 (hr) | ||
AU2014266118B2 (en) | Antibody specifically binding to HER2 | |
HRP20130903T1 (hr) | Heparin-vezujuä†i epidermalnom äśimbeniku rasta sliäśni vezujuä†i proteini antigena äśimbenika rasta | |
RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
JP2013173775A5 (hr) | ||
JP2013520442A5 (hr) | ||
RU2010123888A (ru) | Axl-антитела | |
HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu | |
RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
RU2011117237A (ru) | АНТИТЕЛА ПРОТИВ Notch2 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
WO2016033284A4 (en) | Combination therapy for treatment of cancer | |
JP2020514310A5 (hr) | ||
JP2024016024A5 (hr) | ||
HRP20110374T1 (hr) | Upotreba anti-cd151 antitijela kod liječenja primarnog raka | |
HRP20240213T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd47 | |
JP2019515683A5 (hr) |